Eli Lilly and Company (NYSE:LLY) Holdings Increased by Patrick M Sweeney & Associates Inc.

Patrick M Sweeney & Associates Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 0.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,928 shares of the company’s stock after acquiring an additional 22 shares during the period. Eli Lilly and Company comprises approximately 2.1% of Patrick M Sweeney & Associates Inc.’s investment portfolio, making the stock its 10th biggest position. Patrick M Sweeney & Associates Inc.’s holdings in Eli Lilly and Company were worth $2,651,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Lynx Investment Advisory acquired a new position in Eli Lilly and Company during the second quarter worth $32,000. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth about $26,000. Core Wealth Advisors Inc. increased its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Activest Wealth Management acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $39,000. Finally, Tidemark LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $29,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LLY. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Guggenheim increased their price objective on Eli Lilly and Company from $855.00 to $884.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Berenberg Bank lifted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $948.29.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 1,441 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the completion of the sale, the insider now directly owns 97,367,369 shares of the company’s stock, valued at $89,093,089,982.38. The disclosure for this sale can be found here. Insiders have sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 over the last 90 days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $1.20 on Thursday, reaching $931.58. The stock had a trading volume of 3,047,801 shares, compared to its average volume of 3,102,805. The company has a market cap of $885.38 billion, a P/E ratio of 137.16, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $966.10. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The firm has a fifty day moving average of $875.61 and a two-hundred day moving average of $801.22.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.